Head and Neck Cancer: Advanced PET/CT and MRI Imaging with a Focus on Current and Emerging Molecular Theranostics
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 1 August 2024 | Viewed by 104
Special Issue Editors
Interests: PET/SPECT/CT molecular imaging; radionuclide therapy; genitourinary oncology imaging
Interests: molecular imaging using radiotracers to diagnose diseases; nuclear medicine
Special Issue Information
Dear Colleagues,
A rapidly developing paradigm in cancer therapy involves the use of highly specific molecularly targeted agents for both PET imaging and targeted radionuclide therapy; this is commonly referred to as theranostics. We first review the current means of imaging squamous cell carcinoma of the head and neck using both anatomical imaging and FDG PET, followed by contemporary treatment options. This provides a perspective of where more specific PET imaging and therapy could potentially play a role in advancing patients’ care. We then review the current imaging and therapy used to treat thyroid cancer, followed by how the emerging radiotracers could help. Paragangliomas, rare neuroendocrine tumors of the head and neck, show promising results with targeted somatostatin receptor imaging using DOTATATE. An exciting new class of targeting agents, Fibrinogen Activating Protein inhibitors (FAPi), have shown promising results for imaging squamous cell carcinomas, in addition to many other tumors. Finally, we look at several promising radiotracer ligands under development.
The topics of interest include:
- The anatomic imaging of head and neck squamous cell carcinoma with CT and MRI;
- A review of the radiographic response assessment criteria for head and neck cancer;
- The use of FDG PET for the staging and re-staging of head and neck squamous cell carcinoma;
- The current treatment options for head and neck squamous cell carcinomas;
- The current radioiodine therapy used to treat the thyroid;
- The emerging radiotracers used to image thyroid cancer;
- The role of PET in imaging uncommon head and neck cancers: paraganglioma imaging with DOTATATE PET;
- New radiotracers used to treat head and neck cancer: focus on Fibrinogen Activating Protein ligands;
- A look at the potential theranostic applications in head and neck cancer.
Prof. Dr. Bennett Chin
Dr. Jorge Oldan
Prof. Dr. Steven P. Rowe
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- head and neck cancer
- thyroid cancer
- PET/SPECT/CT molecular imaging
- radionuclide therapy
- nuclear medicine
